# A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

> **NCT05753657** · EARLY_PHASE1 · RECRUITING · sponsor: **Rambam Health Care Campus** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Hyperinsulinism
- Hyperglycemia Drug Induced

## Interventions

- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT05753657
- **Lead sponsor:** Rambam Health Care Campus
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05753657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05753657, "A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05753657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*